The Medical Device Innovation, Safety and Security Consortium (MDISS) recently launched the first of more than a dozen planned device security testing labs and cyber-ranges. The new MDISS World Health Information Security Testing Lab (WHISTL) facilities will comprise a federated network of medical device security testing labs, independently owned and operated by MDISS-member organizations including healthcare delivery organizations, medical device manufacturers, universities and technology companies. Each WHISTL facility will launch and operate under a shared set of standard operating procedures. The goal is to help organizations work together to more effectively address the public health challenges arising from cybersecurity issues emergent in complex, multi-vendor networks of medical devices.

A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of models and which types of sarcomas are most likely to grow as xenografts. The research, which is the first and largest patient-derived orthopedic xenograft (PDOX) study in sarcoma, gives physician-scientists a much-needed roadmap for personalizing therapies for the disease without placing patients at risk for treatment-related complications or ineffective therapy.

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings may provide valuable guidance to women and their physicians about choosing a screening regimen.

The U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR) recently launched a revised web tool that puts important information on cybersecurity breaches into the hands of individuals. The tool is designed to empower them to better identify recent breaches of health information and to learn how all breaches of health information are investigated and successfully resolved.

Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact Treatment Delivery System, the next-generation TomoTherapy platform. The Radixact System replaced a competitive conventional linear accelerator in the single-vault freestanding facility.

August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on ...